The GLP-1 receptor agonist class has transformed metabolic research, but the emergence of dual incretin agonists — specifically tirzepatide — has introduced a mechanistically distinct paradigm. Understanding the differences between these compounds requires examining their receptor binding profiles, downstream signaling, and what published trial data demonstrates.
Receptor Pharmacology: Where They Differ
Semaglutide is a selective GLP-1 receptor agonist with strategic amino acid substitutions extending its half-life to ~7 days. Its mechanism: GLP-1R activation stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic feeding circuits.
Tirzepatide is a 39-amino acid synthetic peptide acting as a dual agonist at both GLP-1R and the glucose-dependent insulinotropic polypeptide receptor (GIPR). Eli Lilly's researchers coined the term "twincretin." Critically, tirzepatide is not simply semaglutide with GIP activity added — it has a distinct molecular structure optimized for balanced agonism at both receptors.
The GIP Receptor: Previously Overlooked
GIP was long considered secondary in incretin biology. The success of tirzepatide has largely overturned this view. At pharmacological doses, GIPR agonism enhances insulin secretion synergistically with GLP-1R; promotes adipocyte lipid handling in a way that improves insulin sensitivity; and acts on hypothalamic circuits distinct from those engaged by GLP-1 to further modulate feeding-circuit signaling.
SURMOUNT vs STEP: Published Study Endpoints
The SURMOUNT-1 and STEP-1 programs each reported body-composition endpoints in their respective study populations, with the dual-agonist arm showing the larger change. The SURPASS-2 study directly compared tirzepatide against semaglutide 1mg and showed dose-dependent differences in insulinotropic signaling and body-composition endpoints across the three doses studied in the referenced trial.
References
- Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med, 387, 205–216.
- Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 384, 989–1002.
- Frias JP, et al. (2021). Tirzepatide versus Semaglutide in Patients with Type 2 Diabetes. N Engl J Med, 385, 503–515.
This article summarizes publicly available research for educational purposes and does not constitute medical advice, a therapeutic claim, or a recommendation for human use. Products referenced are sold for laboratory research use only.